相关实验视频

Updated: Mar 1, 2026

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

8.5K

达科米提尼布作为先进EGFR突变非小细胞肺癌无脑转移的第一线治疗方法:一个多中心回顾性观察性研究

Ping-Chih Hsu1,2, How-Wen Ko1,2, Li-Chung Chiu1,2

  • 1Division of Thoracic Medicine, Department of Internal Medicine, Chang Gung Memorial Hospital at Linkou, Taoyuan City, Taiwan.

Cancer medicine
|February 27, 2026
PubMed
概括

达科米替尼 (dacomitinib) 作为一线治疗EGFR突变的晚期非小细胞肺癌 (NSCLC) 的良好结果. 患者表现不佳或骨/肝转移可能需要不同的策略.

关键词:
这是一种常见的EGFR突变.达科米丁尼布的使用情况皮肤生长因子受体突变非小细胞肺癌 (NSCLC) 是一种非小细胞肺癌.氨酸激酶抑制剂 氨酸激酶抑制剂

更多相关视频

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

9.3K
Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.8K

相关概念视频

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K